Long-read sequencing reveals the RNA isoform repertoire of neuropsychiatric risk genes in human brain

Ricardo De Paoli-Iseppi[1*], Shweta Joshi[1], Josie Gleeson[1], Yair David Joseph Prawer[1], Yupei Yu[1], Ria Agarwal[1], Anran Li[1], Anthea Hull[1], Eloise Marie Whitehead[1], Yoonji Seo[1], Rhea Kujawa[1], Raphael Chang[1], Mriga Dutt[1], Catriona McLean[2,3], Benjamin Leo Parker[1], Michael Ben Clark[1*]

[1]Department of Anatomy and Physiology, The University of Melbourne, Parkville, VIC, Australia

[2]Department of Anatomical Pathology, Alfred Health, Melbourne, Victoria, Australia

[3]Victorian Brain Bank, The Florey, Parkville, Victoria, Australia

*Corresponding authors

Abstract

Neuropsychiatric disorders are highly complex conditions and the risk of developing a disorder has been tied to hundreds of genomic variants that alter the expression and/or products (isoforms) made by risk genes. However, how these genes contribute to disease risk and onset through altered expression and RNA splicing is not well understood. Here we show our current understanding of gene isoforms is far from complete and reveal the precise splicing profiles of neuropsychiatric disorder risk genes. Combining our new bioinformatic pipeline IsoLamp with nanopore long-read amplicon sequencing, we deeply profiled the RNA isoform repertoire of 31 high-confidence neuropsychiatric disorder risk genes in human brain. We show most risk genes are more complex than previously reported, identifying 440 novel isoforms and 28 novel exons, including isoforms which alter protein domains, and genes such as *ATG13* and *GATAD2A* where most expression was from previously undiscovered isoforms. The greatest isoform diversity was present in the schizophrenia risk gene *ITIH4*. Mass spectrometry of brain protein isolates confirmed translation of a novel exon skipping event in ITIH4, suggesting a new regulatory mechanism for this gene in brain. Our results emphasize the widespread presence of previously undetected RNA and protein isoforms in brain and provide an effective approach to address this knowledge gap. Uncovering the isoform repertoire of neuropsychiatric risk genes will underpin future analyses of the functional impact these isoforms have on neuropsychiatric disorders, enabling the translation of genomic findings into a pathophysiological understanding of disease.

Introduction

Over 90% of multi-exonic human genes undergo alternative splicing (AS), a process that enables genes to produce multiple mRNA products (RNA isoforms) [1]. Common AS events include exon skipping, intron retention and alternative 5' and 3' exonic splice sites [2]. These mRNA alterations can impact the open reading frame (ORF) and/or alter post-transcription regulation and translation of an RNA, increasing both transcriptomic and proteomic diversity [1, 3, 4]. AS has been established as an important regulator of organ development and physiological functions and is highly regulated under normal conditions [5, 6]. Conversely, aberrant RNA splicing has been linked to the development of cancer, autoimmune and neurodevelopmental disorders [7-11]. AS plays an especially important role in the brain, which has a distinct splicing program including the largest number of tissue specific exons and frequent use of microexons [12]. Numerous studies have reported crucial roles for AS in brain development and dysregulation in disease [13, 14].

Neuropsychiatric or mental health disorders (MHDs) including schizophrenia (SZ), major depressive
disorder (MDD), autism spectrum disorder (ASD) and bipolar disorder (BD) can carry significant
morbidity for affected individuals [15]. Comorbidities, delayed diagnoses and stigma surrounding
MHDs also present a significant challenge to individuals and their families [16]. However, treatment
options remain limited or are not well tolerated or effective in some individuals and the underlying
aetiology of disease and risk remains poorly understood [17-19]. Recently, large genome wide
association studies (GWAS) have revealed hundreds of common single nucleotide polymorphisms
(SNPs) that are associated with risk of developing neuropsychiatric disease [20-25]. The vast majority
of these variants are found in non-coding parts of the genome and are expected to be regulatory,
impacting gene expression levels or which RNA isoforms are produced. For example, risk variants
could impact splicing factor binding potentially resulting in novel RNA isoforms, gross transcript
alterations or changes to isoform splicing ratios [8]. Confirmatory studies including transcriptome
wide association studies (TWAS), summary data–based Mendelian randomization (SMR) [26],
multimarker analysis of genomic annotation (MAGMA) and variants (H-MAGMA [27], nMAGMA
[28]) and functional genomics have helped to identify the risk genes at these loci and also showed a
considerable number of risk loci are shared between disorders [29]. However, there is a current lack
of understanding about how risk gene expression and splicing are altered by the risk variants and
therefore profiling both their expression and RNA isoforms is essential to link genetic changes to
disease pathophysiology.

Current sequencing technologies including Illumina short-reads perform well at detecting novel AS,
however the lack of long-range exon connectivity information inherent in short-reads means these
approaches are limited in their ability to identify and quantify full-length isoforms and this issue is
exacerbated in longer, more complex genes [30, 31]. In contrast, long-read technologies including
nanopore sequencing from Oxford Nanopore Technologies (ONT) and Pacific Biosciences (PacBio)
single-molecule, real-time sequencing can sequence entire isoforms in a single read enabling more
accurate isoform profiling [7, 32]. Such technologies now make it feasible to comprehensively
examine gene isoform profiles. Initial investigations of *SNX19* and *CACNA1C* demonstrated the
incomplete knowledge of isoform profiles in humans and the likely importance of novel MHD risk
gene isoforms in disease [33, 34].

In this study we addressed the lack of knowledge surrounding MHD risk gene isoform expression
using nanopore amplicon sequencing. We developed a new bioinformatic tool, IsoLamp, to identify
known and novel RNA isoforms from long-read data. Analysis of the RNA splicing profiles of 31
MHD risk genes identified 360 novel RNA isoforms and 28 novel exons. We identified several genes
where most expression is from novel isoforms, including *ATG13* and *GATAD2A*, where the most
highly expressed isoforms were novel. Our results show the transcript structure for most risk genes is
more complex than current annotations, containing additional exon skipping events, retained introns,
novel splice sites and novel exons, including novel isoforms that alter the protein and potentially its
function. This work lays the foundation for a better understanding of how risk gene isoforms may play
a role in disease pathophysiology.

Methods

Sample preparation and QC

Healthy control post-mortem human brain samples were obtained from six individuals collected
through the Victorian Brain Bank (VBB) under HREC approval #12457. Brain samples from two
further individuals with a non-control phenotype were also obtained from the VBB for protocol
testing and validation purposes. Age, sex and additional details including the post-mortem interval
(PMI), pH and tissue weight are shown in Supplementary Table 1. Briefly, samples comprised 5
males and 1 female, age range: 51 – 72 yrs, PMI range: 31 – 64 hrs and pH range: 5.7 – 6.7. Frozen

tissue (weight range: 57 – 135 mg) was cut from seven brain regions including Brodmann areas (BA),
BA9 (dorsolateral prefrontal cortex (DLPFC)), BA46 (medial prefrontal cortex (MPFC)), BA10
(fronto-parietal cortex (FPC)), Brodmann Area 24 (dorsal anterior cingulate cortex (dACC)), caudate,
cerebellum and temporal cortex. Total RNA was extracted from bulk tissue in eight randomised
batches of 3 – 6 samples. First, frozen brain tissue was homogenised on ice, using a manual tissue
grinder (Potter-Elvehjem, PTFE), whilst immersed in 1 mL QIAzol Lysis Reagent (QIAGEN). Lysate
was then processed using a RNeasy Lipid Tissue Kit (QIAGEN, 74804), according to the
manufacturers' instructions. Isolated RNA quality and quantity was checked using a Qubit 4
Fluorometer (2 μL), TapeStation 4200 (RNA integrity number equivalent (RINe), cut-off = 6) and
Nanodrop 2000.

Database curation and risk gene selection
MHD risk genes were selected for long-read amplicon sequencing using an internal database that
aimed to collate evidence from the literature of gene involvement in disease risk from the original
GWAS, meta-analyses including MAGMA (and variants including eMAGMA, hMAGMA,
nMAGMA), TWAS, SMR and follow-up studies including fine mapping, protein-protein interaction
(PPI), epigenetic (DNA methylation) and targeted experimental validation (Supplementary Figure 1).
The foundation of this database was a list of significant GWAS SNPs for SZ, BD, MDD and ASD.
Association data was downloaded from the NHGRI-EBI GWAS Catalog [35]. MHD GWAS
associations were filtered on the 'Disease/Trait' column to exclude effects of treatments including
pharmaceutical, mixed disorder studies and associations with behavioural traits like smoking or
alcohol intake. Associations were excluded if both the 'reported gene' column was 'not reported
(NR)' and the 'mapped gene' column was blank. Date data was downloaded, filters applied, and
percentage associations retained are detailed in Supplementary Table 2.

Follow-up studies and experiments were then identified in the literature and the reported genes were
manually collated and assigned to an 'evidence' category as described above. Each evidence category
had the following information headers including the PubMed ID of the reporting manuscript, the first
author and the reported SNP and gene. An R script (Supplementary File 1) was used to curate risk
genes and appearances in unique studies. Counts of reported risk genes and unique studies, for each
evidence category, were then combined with the original GWAS table. Risk genes were then sorted
by evidence (high to low), separately for each MHD. A multi-trait evidence list was also made by
combining each MHD table together and again sorting by descending evidence. This gave us
flexibility to focus on risk genes that appeared to be specific to a single MHD or those with shared
risk across disorders.

Primer design, cDNA synthesis and long-range PCR
Thirty-one (31) MHD risk genes were selected from our database and the full coding sequence (CDS)
from the canonical isoform was downloaded from the UCSC Genome Browser [36]. Primers, located
in the 5' and 3' UTRs, were designed to amplify the CDS using Primer3 Plus [37]. Additional primers
were made to amplify alternative start or end sites that were not captured by a single primer pair.
Additional UCSC track sources including expressed sequence tags (EST), transcript support level
(TSL), APPRIS designation, human mRNA support, cap-analysis of gene expression (CAGE) peaks,
CpG islands and H3K4Me3 marks were examined to ensure there was enough evidence that
alternative start or end sites were real before a primer was designed [38]. All primers, primer
combinations and modified Primer3 Plus settings are listed in Supplementary Table 3. Risk gene
primers from Primer3 Plus were aligned to tracks on the UCSC Genome Browser using BLAT for
visualisation and tested using the In-Silico PCR [39].

To amplify risk gene CDS, 1 μg of total RNA was used as template for cDNA synthesis using
Maxima H Minus Reverse Transcriptase (Thermo Fisher Scientific, EP0752, 200 U/μL) according to
the manufacturers' instructions. Two duplicate cDNA plates were generated simultaneously to reduce

variability and provide enough template for multiple risk gene PCRs. Risk genes were amplified using one of following DNA polymerases; LongAmp® Taq 2X Master Mix (NEB, M0287S), Platinum™ SuperFi II PCR Master Mix (Thermo Fisher Scientific, 12368010) or PrimeSTAR GXL (TakaraBio, R050B). Each set of gene primers were individually optimised by adjusting PCR cycling conditions (Supplementary Table 3) until sufficient pure template (~1 – 10 ng) could be produced for input to barcoding. Short-fragments and primer-dimer were removed prior to barcoding using AMPure XP beads (Beckmann Coulter) at 0.5 – 0.8x ratios to PCR volume. An overview of the experimental protocol is shown in Figure 1A.

Long-read amplicon sequencing

Barcoding conditions for sample multiplexing (N=35, EXP-PBC096, ONT) and library preparation for long-read sequencing followed the recommended ligation sequencing protocol (Figure 1A) (SQK-LSK109/110, ONT). All barcoding PCR was done using LongAmp® Taq 2X Master Mix with an amplicon specific extension time (approximately 1 min/Kb) and 10 – 15x cycles. AMPure clean-up following adaptor ligation was adjusted from the default ratio of 0.4X depending on the length of the target amplicon. Adaptor ligated libraries were loaded (25 – 35 fmol) onto MinION (FLO-MIN106) flow cells and a minimum of 10,000 reads per sample were targeted before flushing and storing the flow cell. All runs were re-basecalled using the super-accurate (SUP) basecalling model (Guppy v6.0.17, 2022) and minimum qscore = 10.

Isoform discovery from long-read amplicon sequencing with IsoLamp

We developed a new bioinformatic pipeline, IsoLamp, for the analysis of long-read amplicon data (Figure 1B). First, pass reads were down sampled [40] to a consistent number (8000) per barcode and mapped to the reference genome with minimap2 (v2.24) [41]. Then, low accuracy reads (< 0.95) were removed and samples were merged prior to isoform identification. Read accuracy was calculated using CIGAR strings in the BAM files and is defined as: ('X'+'='+'I'+'D'-'NM')/('X'+'='+'I'+'D'). Next, the merged BAM file of high accuracy reads was used as input for isoform discovery with Bambu (v3.2.4) using the following parameters: novel discovery rate (NDR) = 1 and min.fractionByGene = 0.001 [42]. Next, isoforms identified with Bambu were filtered to remove any with zero expression and to retain only isoforms with start and end positions overlapping the known primer coordinates using bedtools intersect (v2.30) [43] to retain only isoforms with start and end positions overlapping the known primer coordinates. Finally, the remaining isoforms were used to create an updated transcriptome with GffRead (v0.12.7) [44], and reads from each barcode were quantified with salmon in alignment-based mode (v0.14.1) [45, 46] and isoforms were annotated with GffCompare (v0.12.6) [44]. The pipeline outputs a list of isoform annotations (.gtf), isoform expression as transcripts per million (TPM) and proportion of overall gene expression, as well as a report summarising the results. An optional TPM filter was also applied to further filter isoforms which required a minimum TPM of 5000. If the user specifies a grouping variable for their input samples, a t-test is performed between isoform proportions between groups and p-values are adjusted for the false discovery rate (0.05).

A

B

Figure 1A. RNA isoform sequencing of human post-mortem brain. RNA was isolated from frontal cortical
regions, caudate (CAUD) and cerebellum (CBM) and converted to cDNA. The coding sequence (black boxes)
was amplified using specific forward (Fwd, yellow arrows) and reverse (Rvr, pink arrow) primers generally
designed in the 5' and 3' UTR regions (grey boxes) to capture as many isoforms as possible. An Oxford
Nanopore Technologies (ONT) adaptor sequence (blue box) was incorporated into each primer for sample
multiplexing. Samples were then barcoded and pooled to create a single library for long-read sequencing on a
GridION. Key: Brodmann Area (BA), barcode (BC), Oxford Nanopore Technologies (ONT). **B. Isoform discovery**
with long-read amplicon sequencing (IsoLamp) workflow. A gene specific parameters file (containing
chromosome and primer coordinates) was used to align long-reads for each sample (B1-3) against the
reference (black box) using Minimap2. Known and novel RNA isoforms were identified using Bambu. Identified
isoforms are then filtered (grey isoforms) on correct forward (yellow line) and reverse (pink line) primer
position ensuring full-length isoform discovery. Low expression (blue on heatmap) isoforms were also filtered
out as indicated by dashed red lines. Filtered known and novel isoforms can then be annotated, quantified
using IsoLamp output files and visualised using IsoVis.

We benchmarked the performance of the IsoLamp pipeline using Spike-in RNA Variant (SIRV) Set 1
synthetic RNA controls (Lexogen). SIRV isoforms are present in three mixes (E0, E1, E2) that
contain isoforms in varying known concentrations. Primers were designed to amplify from the first to
the last exon (as described above) of SIRV5 and SIRV6 genes from cDNA generated in triplicate
from each SIRV mix (N=27) (Supplementary Figure 2). PCR amplification conditions for SIRV
amplicons are shown in Supplementary Table 4. Samples were barcoded and sequenced as described
above, and subsequent basecalling and demultiplexing was performed with Guppy (v6.0.17, SUP,
2022). The IsoLamp pipeline was compared against three other isoform discovery tools: StringTie2
[47], FLAIR [48] and Bambu (using both default parameters and the optimised parameters used in
IsoLamp). The sensitivity, specificity, accuracy and correlations (expected versus observed counts) of
the programs were compared using three SIRV reference annotations: complete (C), incomplete (I)
(missing isoforms, to test ability to recover unannotated true positive isoforms) and over (O) (extra
isoforms, to test ability to minimise false positive annotated isoforms). Novel isoforms were
categorised using SQANTI (v4.2) against the human reference (GENCODE release 41,
GRCh38.p13). Finally principal component analyses (PCA) were done on a combined dataset of
expression values for each known and novel isoform and its associated metadata including brain
region, gene, RINe, pH, individual, PMI and age.

Novel exon validation

Nanopore long-read supported novel exons were validated by RT-PCR. Amplicons were designed
from the known 5' flanking exon into the novel exon and from the novel exon into the known 3'
flanking exon. An amplicon spanning the known 5' and 3' flanking exons was used as a positive
control. Primers were designed using Primer3 [37] and checked using Primer BLAST [49] and are
listed in Supplementary Table 5. In some cases, the primer design space was restricted by the novel
exon sequence length and/or nucleotide composition. Novel exon amplifications were done using *Taq*
2X MasterMix (NEB, M0270L) and cycling conditions can also be found in Supplementary Table 5.
PCR products were visualised via gel electrophoresis using GelGreen® Nucleic Acid Stain (Biotium,
41005) and GeneRuler 100 bp ladder (TFS, SMN0243). PCR products in the expected size range were
cleaned up using AMPure XP Reagent (Beckmann Coulter, A63881) at a 1.8X ratio to remove
fragments <100 bp and sent for Sanger sequencing (100 – 200 bp, AGRF).

Protein isolation and novel sequence detection using targeted mass spectrophotometry (MS)

Post-mortem frontal cortex and cerebellum brain samples (mean weight = 53.25 mg) were used for
protein isolation. Samples were from a healthy 59 yo female and 74 yo male with PMIs of 30 and 22
hrs respectively who had no known neurological or neuropsychiatric conditions. Briefly, samples
were lysed in 500 µL of guanidinium-HCl buffer using tip-probe sonication, heated briefly to 95 ℃
and diluted 1:1 with LC-MS water before 4 mL of ice-cold acetone was added to precipitate protein
overnight at -30 ℃. Supernatant following a wash (3 mL 80% cold acetone) and incubation (-30 ℃, 1
hr) was discarded and protein air-dried (RT, 30 mins). The protein pellet was resuspended in 500 µL
10% TFE in 100 mM HEPES (pH 7.5) and sonicated. Protein concentration was estimated with BCA
(1 µL sample + 9 µL 2% SDS). Normalised protein (10 µg/10 µL) was then digested using a
combination of LysC/trypsin or GluC for all samples. Finally, digested peptides were analysed using
an OrbiTrap Eclipse mass spectrophotometer using known peptide targets informed by long-reads.
Protein structure prediction was done using AlphaFold accessed through UCSF ChimeraX (v1.5) [50-
52].

Data visualisation

238 The publicly available web-tool IsoVis (v1.1, https://isomix.org/isovis/) was used to visualise RNA
239 isoforms and associated expression data (Wan et al., 2024, *under review*). Known and novel RNA
240 isoforms are represented as a stack to compare alternative splicing events between different isoforms.
241 Read counts assigned to each RNA isoform for each of the 35 samples were visualised as a heatmap.

Results

Experimental overview

To identify the RNA isoforms expressed from genes of interest we aimed to perform long-read amplicon sequencing, which provides a highly sensitive means for comprehensive isoform discovery and relative quantification (Figure 1A) [33]. We selected seven regions of post-mortem human brain, encompassing both transcriptionally divergent regions as well as those highly implicated in MHDs. Amplicons were designed cover the full coding region of target genes and, where possible, run from the first to the last exon. Multiple set of primers were used for genes with alternative transcriptional initiation and termination exons and/or alternative coding sequence initiation and termination sites.

IsoLamp: a tool for RNA isoform discovery from long-read amplicon sequencing

While there are several long-read isoform discovery and quantification tools, these are not generally optimised for amplicon sequencing of single genes at high depth. Therefore, we created ISOform discovery with Long-read AMPlicon sequencing (IsoLamp), a custom pipeline designed for isoform profiling from amplicon sequencing (Figure 1B). In contrast to previous tools [33] IsoLamp can be applied to any gene, provides flexible filtering options and provides a simpler, unified, output of isoforms.

We benchmarked the performance of IsoLamp using synthetic Spike-in RNA variants (SIRVs) that provide a known ground truth for isoform exonic structures and abundances. We performed long-read amplicon sequencing on SIRV5 and SIRV6, targeting five isoforms per gene, as these SIRVs allowed targeting of the largest number of isoforms with a single primer pair and so best recapitulated human genes. The SIRV dataset comprised nine replicates from each of the three SIRV mixes (E0, E1, E2) for each gene. 99% of reads mapped to the SIRV genome with minimap2 [41], confirming on-target amplification. We benchmarked the performance of IsoLamp with Bambu [42], FLAIR [48], FLAMES [53] and Stringtie2 (-L) [47]. We assessed the precision, recall and expression correlations of the five tools using three different reference annotations (Figure 2A-C, Supplementary Figure 3, Supplementary Table 6): **1.** Complete - contains all SIRV isoforms, **2.** Insufficient - missing SIRV isoforms known to be present, and **3.** Over – contains additional isoforms that are not present in the SIRV mixes.

Our benchmarking results demonstrated IsoLamp had the highest precision and recall values, consistently outperforming other isoform discovery tools by correctly identifying true isoforms and minimising false positives (Figure 2A, Supplementary Table 6). This included maintaining high performance with the more challenging, but also more realistic, insufficient and over annotation references. IsoLamp expression quantification was also consistently accurate and maintained performance irrespective of the annotation provided (Figure 2B, C).

Bambu, which is also utilised within the IsoLamp pipeline, was the next best performing tool although it identified more false positives and had poorer recall and quantification results using the insufficient annotation (Figure 2A-C). IsoLamp utilises Bambu parameters optimised for amplicon-sequencing, including a novel discovery rate (NDR) of 1. Adjusting the Bambu 'NDR' to 1 improved its recall but didn't improve precision (Figure 2A-C, Supplementary Table 6). These results demonstrate how IsoLamp outperforms tools designed for whole-transcriptome analysis, including when Bambu is provided with optimised isoform discovery parameters for amplicon sequencing.

FLAIR had the highest number of isoforms of all tools tested identifying 261, 181, and 278 novel transcripts in the complete, insufficient, and over-annotated reference-based analyses, respectively. This high level of false-positive novel transcripts led to inaccuracies in transcript abundance assignments, resulting in low correlations compared to other tools (Figure 2A-C). FLAMES exhibited 100% recall for SIRV5 across all annotations, however, its performance with SIRV6 was suboptimal, indicating a higher degree of variability in the FLAMES isoform discovery pipeline. FLAMES also performed

poorly for isoform quantification. Lastly, while Stringtie2 did not introduce large numbers of false
positives, it had the highest number of false negatives, including when provided with complete
annotations (Figure 2A-C, Supplementary Table 6).

IsoLamp employs an optimised expression-based filter to remove lowly expressed isoforms that are
likely to be false positive detections. Applying this filter to Bambu, FLAIR, and FLAMES
substantially reduced false positive novel isoforms and enhanced overall precision (Supplementary
Figure 3, Supplementary Table 6), though IsoLamp was still the top performing tool. Beyond
synthetic benchmarking data, reference annotations are typically a combination of insufficient and
over annotations. In such scenarios, IsoLamp demonstrated better or comparable correlations with all
other tools (Figure 1A-C, Supplementary Figure 3), suggesting its superiority for amplicon-
sequencing based isoform discovery and quantification from real biological data.

Figure 2. Benchmarking IsoLamp using spike-in SIRVs. A. Precision recall of each tested pipeline with the
complete, insufficient or over annotated SIRV reference. IsoLamp (black) returned high quality isoforms from
amplicon data of both SIRV5 and 6. Pearson **(B)** and Spearman **(C)** correlations for each pipeline between
known and observed expression values for SIRV 5 and 6 mixes.

Post-mortem human brain RNA quantity and quality
Total RNA for long-range amplicon sequencing was extracted from 7 brain regions from 5 healthy
individuals (Ind01 - 05) and subject to sample QC (Supplementary Figure 4A-D). RINe (mean = 7.4,
range = 6 - 8.1) did not differ by brain region, however Ind04 had significantly lower RINe scores
(Supplementary Figure 4B). No trend between the PMI (mean = 44.25 hrs) and RINe was observed
(Supplementary Figure 4C). RINe appeared to worsen with decreasing brain tissue pH levels
(Supplementary Figure 4D). A principal component analysis (PCA) showed separation of Ind04

(likely driven by lower sample pH and RINe) and of cerebellum and caudate samples from cortical
regions in PC1 and PC2 (Supplementary Figure 5AB). A relatively small proportion of variance
(4.7%) was attributed to control donor age in PC5 (Supplementary Figure 5C).

Long read sequencing identifies 360 novel RNA isoforms

A total of 31 risk genes were selected for amplicon sequencing based on the accumulated evidence for
their involvement in neuropsychiatric disorder risk. A custom database of risk genes and their
evidence levels was created and genes ranked (Methods). In a reflection of current GWAS cohort
sizes, 21 of the selected genes had the highest evidence for involvement in risk for SZ, 7 for MDD, 2
for ASD and 1 for BPD (Figure 3A). Evidence from GWAS, TWAS and other studies show that some
genes appear to be risk factors for multiple disorders including *KLC1* for SZ, MDD and ASD (Figure
3B).

A

B

Figure 3. Selection of high-confidence MHD risk genes for amplicon sequencing. A. Risk genes included in this
study classified by the disorder for which they have the highest evidence of association. **B.** Sequenced genes
and their evidence levels for each MHD. The evidence count was calculated as the sum of independent analysis
types for example, GWAS, MAGMA, TWAS, SMR, DNA methylation, fine mapping, protein-protein interaction
and targeted validation studies, that supported gene involvement in risk for a particular disorder. #Indicates re-
sequencing of a gene from a previous study (Clark *et al.* 2019).

The full RNA isoform profile for each gene was sequenced using nanopore long-read amplicon sequencing. Mapping accuracy ranged from 93.7% (*CLCN3*) to 97.5% (*SORCS3*) (Supplementary Figure 6A, B). Each novel isoform and its predicted impact on known protein domains, open reading frame (ORF) and associated instability index was recorded (Supplementary File 2) and visualised using IsoVis (Supplementary File 3) (Wan et al., 2024, *under review*). With no TPM filter set in IsoLamp we identified 872 known and novel isoforms across all 31 neuropsychiatric disorder risk genes. To filter this list for more highly expressed novel isoforms we applied a TPM filter which resulted in 440 known and novel isoforms across all genes (Figure 4A). Of these, SQANTI [54] classified 80 as known (full splice match (FSM)), 266 as novel but using only known splice sites or junctions (novel in catalogue (NIC)), and 95 as containing at least one novel splice site (novel not in catalogue (NNC)) (Figure 4A).

We next asked what proportion of reads for each gene were assigned to novel isoforms (Figure 4B). This ranged widely from approximately 96.9% for *GATAD2A* to 0% for *GRIN2A*, which was the only gene for which no novel RNA isoforms were detected. Approximately one quarter (7/31) of genes investigated had most of their gene expression assigned to novel isoforms, demonstrating how isoforms and their expression profiles for many genes are still poorly understood. As our amplicon-sequencing does not encompass all variations in transcriptional initiation and termination sites, these results can be seen as a lower bound for novel isoforms and their expression proportions. Linear regression of gene isoform counts (Supplementary Figure 7) and novel isoform proportion did not reveal a significant relationship with amplicon length or canonical exon count, indicating that detection of novel isoforms is largely gene dependent (Supplementary Figure 8A-D). To determine what was different about the splicing pattern of each novel isoform we further sub-classified them using SQANTI, based on the use of a combination of known exon junctions (COJ) or splice sites (COS), retained intron (RI) or containing at least one novel splice site (ALO) (donor, acceptor or pair) [54]. Overall, the most reads were assigned to "novel combination of known junctions", where all individual exon combination were known but the entire chain of exons was novel. The type and proportion of novel isoforms from each category was highly gene specific, demonstrating a wide variety of novel RNA types missing from current gene annotations.

A

B

C

Figure 4. A. The total number of known and novel isoforms identified across all 31 risk genes. SQANTI
structural categories are known/full splice match (FSM), novel in catalogue (NIC) and novel not in catalogue
(NNC). **B.** Proportion of reads for each gene as classified by the SQANTI sub-category. **C.** Count of predicted
outcomes for novel isoform subcategories. Expasy (Gasteiger *et al.*, 2003) was used to examine the open
reading frame (ORF) of novel isoforms (SQANTI structural category: novel not in catalogue (NNC) or novel in
catalogue (NIC)) using the canonical start and stop as a reference. Predictions were categorised as coding if the
ORF was retained, nonsense mediated decay (NMD) if a premature termination codon was present and not
within 50 nt of the final exon junction or unknown (unkn) if there was not enough information. Novel isoform
SQANTI subcategories (subcat) are, at least one novel splice site (ALO), intron retention (IR) and combination
of known junctions (COJ) or splice sites (COS).

The impact of each novel isoform on the encoded ORF was examined using Expasy [55] and recorded
as retaining the canonical or other known reading frame (coding), likely-NMD or unknown. Novel
isoforms were classified as coding for 54.2%, 67.3% and 75.4% for ALO, COJ and COS
subcategories respectively. We identified 49 novel isoforms that contained retained introns, 39 (83%)
of which were predicted to lead to NMD (Figure 4C).

Isoforms that contained 'at least one novel splice site' (ALO) generally contained a novel deletion
within a known exon or had novel donors and/or acceptors. All novel junctions in ALO isoforms were
canonical GT-AG, GC-AG or AT-AC junction pairs, though often only the splice donor (GT) or
acceptor (AG) was novel (Supplementary Figure 9A). We found that ~47% of ALO isoforms
contained either a single novel splice donor or acceptor. Novel GC-AG pairing was detected in two
SZ risk genes, within the 5'UTR of *GABBR2* and the donor site of a novel exon in *RFTN2*. These
results show a clear advantage of using long-read sequencing to contextualise novel splice sites which
aids in predicting the outcome on the isoform and ORF.

Detection of highly expressed novel isoforms
A key question regarding novel isoforms is whether they are expressed at high enough level to impact
the biological function of a gene. This is a complex question, because a novel isoform could be low at
the tissue level but highly abundant in a specific cell type, or multiple expressed novel isoforms can
be significant cumulatively, especially if they all encode the same change to a protein. Therefore, we
focused on genes with significant individual or cumulative expression of novel isoforms (analysis on
all gene isoforms is available in Supplementary File 2).

We identified 22 novel isoforms for the schizophrenia risk gene autophagy-related protein 13
(*ATG13*). Novel isoforms represented 64% of gene expression, compared to 36% for full-splice
matches. The most abundant class of novel isoforms (15/22) were COJ, which made up 55.4% of gene
expression (Figure 4B). *ATG13* had two alternative splicing hotspots, firstly with the 5'UTR and
secondly around a predicted disordered region involving exons 12 and 13 in the canonical isoform.
Across all brain regions the most highly expressed isoform was the novel COJ transcript 26 (Tx26),
which represented 23% of total reads, surpassing the canonical transcript ENST00000683050
(12.8%). Tx26 differs from the canonical transcript by skipping of exon 12. It contains the same CDS
as ENST00000359513 but includes an additional exon in the 5'UTR (exon 3). Novel COJ transcripts
6 and 8 also had high read counts and together accounted for 16.6% of expression. These isoforms
were novel due to a combination of 5'UTR exons not previously seen within full-length GENCODE
annotations (Figure 5A, B).

The schizophrenia risk gene CUB and sushi multiple domains 1 (*CSMD1*) was the longest CDS we
amplified at approximately 10,838 nt encompassing 70 coding exons. In total 8/9 detected isoforms
were classified as novel. Following the canonical isoform (ENST00000635120, 51.5% of reads),
novel transcripts 26 (COJ) and 33 (ALO) accounted for 38.3% and 7.1% of assigned reads,

respectively (Figure 5C, D). Novel Tx26 skipped known exon 65 which encodes a sushi 28 extracellular domain and glycosylation site. The ORF of Tx26 retained the reading frame encoding a 3549 amino acid (aa) protein. Novel Tx33 contained a novel splice donor (GT, -8 nt) in canonical exon 21 predicted to lead to a PTC in canonical exon 22. The full Tx33 mRNA also skipped canonical exon 65. *CSMD1* also provides a useful example of the benefit of long read for profiling isoforms. GTEx isoform expression data (https://www.gtexportal.org/home/gene/CSMD1) for *CSMD1* in brain is almost exclusively assigned to isoforms with downstream transcriptional initiation sites (including the two-exon fragment ENST00000521646), despite splice junction level expression largely supporting expression from the canonical start site. The emphasises the difficulty of assembling and quantification expression of full-length isoforms from long, complex genes, which can be achieved using long isoform spanning reads.

The chromatin remodelling subunit and shared SZ and BPD risk gene GATA zinc finger domain containing 2A (*GATAD2A*) had one of the highest proportions of reads (96.9%) assigned to novel isoforms. Most novel isoforms were predicted to be coding COJs (10/24) and these also accounted for the majority of novel read assignment (66.6%). Novel Tx17 had the highest expression level (22.7%) of any *GATAD2A* isoform and skipped canonical exon 10 which overlaps a CpG island (212 nt, 21.7% CpG) and contains a disordered, polar residue biased region and a phosphorylation site (Figure 5E). Two additional novel isoforms (Txs 8 and 12), together accounting for 19.9% of expression, incorporated a known 89 nt 5'UTR exon (ENST00000494516) into full-length isoforms for the first time, clarifying the isoforms expressed from this gene.

Our results were also useful for several genes in identifying the probable isoforms represented by GENCODE transcript fragments. For the SZ risk gene clusterin (*CLU*), the novel Tx1 (COJ) extended ENST00000520796 to the canonical stop codon and suggested this isoform is moderately abundant (8.2% of TPM) across all brain tissues. The ASD risk gene microtubule associated protein tau (*MAPT*) novel Tx5 extended ENST00000703977 and further demonstrated that inclusion of canonical exon 7 (chr17:45,989,878-45,990,075) does not always exhibit coordinated splicing with canonical exon 5. This isoform had a moderate read count comprising 3.2% of *MAPT* expression.

The full RNA isoform profile for the SZ risk gene calcium voltage-gated channel subunit alpha1 C (*CACNA1C*) has previously been reported and was repeated in this study [33]. In total, we identified 5 annotated and 22 novel isoforms. The most highly expressed novel isoform identified in our previous study, novel 2199, now known as ENST00000682835.1 was also identified in our samples and exhibited similar cerebellar specific expression. Importantly, 10 novel isoforms replicated one of two alternative splicing events in a hotspot identified previously in canonical exon 7 [33]. This hotspot contains the canonical splice site and two alternative 3'SS acceptors over only 12 nucleotides (chr12: 2,493,190-2,493,201) (Supplementary Figure 10).

456 A

458 B

459
460
461 C

463 D

464
465
466
467

E

Figure 5. Highly abundant novel isoforms and the predicted mRNA outcome. (A,C,E) mRNA splice graphs.
Dark and light grey boxes indicate 5' and 3' UTR and coding exons respectively. Numbers indicate the coding
exon. Orange lines (pre-mRNA) and boxes (mRNA) indicate novel splicing events. mRNA isoforms depict known
isoforms (ENST) against novel (Tx) isoforms, ".." indicates abbreviated zeroes. **(B,D)** IsoVis visualisation of
Isoform structures (centre stack) and expression levels (heatmap). Canonical isoform shown at top of stack
including exonic mapping of protein domains (purple) and disordered regions (green) **A.** Splice graph of *ATG13*
highlights the open reading frame (ORF) preserving skipping event of canonical exon 12. **B.** High expression of
ATG13 novel transcript 26 (Tx26). **C.** Splice graphs of *CSMD1* novel transcript 26 (Tx26) and 33 (Tx33) changes
located within highlighted pink regions for clarity. The ORF retaining skipping event of canonical exon 65 may
disrupt a known glycosylation site (black bar), a sushi domain extending from exon 64 (blue) and part of an
extracellular domain (green). Tx33 contains a novel splice donor (-8 nt) within exon 21 leading to a premature
termination codon (PTC) in exon 22. Dashed lines indicate continuation of the transcript to 5' or 3' coding
exons. **D.** Relatively high expression of *CSMD1* novel transcripts 26 and 33. **E.** *GATAD2A* novel transcript Tx17
contained a novel, ORF retaining, skipping event of canonical exon 10 which contains a phosphorylation site
(black bar), part of a polar biased region (blue) and overlaps a CpG island (<300 bp, green). Dashed lines
indicate alternative splicing of 5'UTR exons.

Novel isoforms alter predicted protein structures
Novel isoforms have the potential to affect post-transcriptional regulation, protein sequence, structure
and function or both. We next investigated a selection of isoforms that would be predicted to lead to
protein changes to understand their possible impact.

Several novel isoforms (including 5 of the top 20 by expression, Supplementary File 3R) predicted a
novel exon 22 skipping event in the SZ risk gene *ITIH4*. Targeted mass spectrophotometry confirmed
a novel junction between exons 21 and 23 (ETLFSVMPG//PVLPGGALGISSSIR) created due to
skipping of exon 22 (Figure 6A). This event was predicted to encode a PTC <50 nt from the final
exon junction, indicating it may not be directed to NMD. Protein structure prediction of the canonical
(ENST00000266041.9) and a representative novel isoform (Tx71) indicated a loss of 106 aa (~44%)
of the 35 kDa heavy chain domain but retention of three O-glycosylation sites (Thr:719, 720, 722)
(Figure 6B-D). Novel transcript 71 accounted for ~3.7% of *ITIH4* TPM and this skipping event was
found in an additional 24/68 (35.2%) novel isoforms which together accounted for 23.4% of reads.
Tx71 also skipped canonical exons 15 and 16, which contain a protease susceptibility region (residues
633 - 713) and a MASP-1 cleavage site (645 - 646: RR) [56]. Cleavage at this site and subsequent
formation of an ITIH4-MASP complex can inhibit complement activation via the lectin pathway [56].
However, skipping of canonical exon 22 was not mutually inclusive with skipping of exons 15/16 as
other novel isoforms with exon 22 skipping retained exons 15/16. The absence of much of the 35 kDa
heavy chain domain is likely to impact on ITIH4 protein function and further studies will be required
to examine if it plays a role in neuronal phenotypes.

Ten novel isoforms were identified for the SZ risk gene glutamate metabotropic receptor 3 (*GRM3*).
Three novel isoforms (Txs 6, 7, 9) skip exon 2 which contains the canonical translation start site and
instead could use an alternative, frame retaining, translation initiation site in exon 1, extending the
truncated reference isoform ENST00000454217.1 which is also supported by human amygdala
mRNA (AK294178) (Supplementary File 3Q). Translation of these isoforms would likely cause

significant disruption to the resultant protein with removal of the signal peptide, transmembrane domain and disulphide bonds. Cumulatively these novel isoforms accounted for a relatively low 8.8% of expression when compared to the canonical isoform (86.5%).

Both novel isoforms and exons were identified for the shared MDD and ASD risk gene neuronal growth regulator 1 (*NEGR1*). Most reads (83.5%) were assigned to the canonical *NEGR1* isoform (ENST00000357731, 354 aa). Three novel isoforms were identified, two of which (Txs 1 and 2) contained novel exons (Supplementary Figure 11A, B). These transcripts accounted for 9.4% (Tx2) and 5% (Tx1) of read counts. Both novel exons were located between cassette exons 6 - 7 and were validated using Sanger sequencing. The novel exon within Tx1 was 42 nt (14 aa) in length, had high 100 vertebrate conservation (UCSC) and was predicted to be frame retaining (Supplementary Figure 11C). Protein structure prediction of the 368 aa Tx1 using AlphaFold [50] showed a 14 aa extension near the C-terminal prior between the GPI anchor (G:324 aa) and the three immunoglobulin-like domains (Supplementary Figure 11D). In contrast, the 58 nt novel exon within Tx2 encoded a PTC (TAG) only 35 nt distant to the final exon junction complex, suggesting it might not trigger NMD. Truncation of the protein at this position (313 + 7 novel aa) would remove the GPI anchor potentially creating a near complete protein (320 aa) that is unable to attach to the cell membrane (Supplementary Figure 11E).

Brain region specific expression of novel isoforms

Many isoforms have brain region enriched or specific expression [57, 58]. Our amplicon sequencing approach identifies the presence and relative expression proportion of different isoforms. We next asked if any novel risk genes isoforms showed expression differences between brain regions. Overall, cerebellum exhibited most differences in isoform expression, consistent with previous whole transcriptome results [12].

Depression risk gene DCC netrin 1 receptor (*DCC*) novel isoform Tx9 had significantly higher TPM in cerebellum (Figure 7A, Supplementary File 3J). TPMs of Tx9 in CBM were approximately 10x higher than the average for cortical regions and 3x higher than in caudate. This isoform, classified as a COJ and predicted to encode a 1425 aa protein, accounted for ~5% of *DCC* expression. Tx9 uses an alternative 3'SS (-60 nt) in cassette exon 17 and the skipped nucleotides cover an extracellular region and fibronectin type-III domain (UniProt). The SZ risk gene double C2 domain alpha (*DOC2A*) had two novel isoforms with significant variation in brain specific expression including Tx8 in cerebellum and Tx41 in caudate (Figure 7B, C, Supplementary File 3K). Novel Tx8 used a novel splice donor in canonical 5'UTR exon 1 (GT, +158 nt) and was predicted to encode a 400 aa protein unchanged from the canonical transcript. Tx41 was the only novel transcript that showed moderate but specific expression in caudate samples or any tissue other than cerebellum. Tx41 extends the known isoform ENST00000574405 to the canonical stop and is predicted to encode a 400 aa protein. Overall, 28 novel isoforms in 11 risk genes were found to have variable expression amongst brain tissues supporting a role for these isoforms within specific brain regions or potentially in a subset of cells.

551 **A**

553 **B**   **C**

562 **D**

Figure 6. *ITIH4* **canonical and novel isoform protein structure predictions. A.** IsoVis stack of the top seven
ITIH4 isoforms sorted by expression. Several novel isoforms contained the novel exon 22 skipping event (red
box) including Txs71 and 94. **B.** Canonical isoform (ENST00000266041, UniProt:Q14624) structure prediction
indicating 70 kDa (orange) and 30 kDA (blue) chains **C.** Novel isoform (Tx71) structure prediction indicating 70
kDa chain (orange), truncated 30 kDA chain (blue), O-glycosylation sites (green), novel splice junction peptide
detected using mass spectrophotometry (red) and novel peptides (pink). Black arrow indicates termination <50

nt from the final exon junction complex. **D.** AlphaFold per-residue confidence scores (pLDDT) (0-100) for *ITIH4*

novel transcript 71: very high (>90, blue), confident (90-70, light-blue), low (70>50, yellow) and very low (<50,

orange).

Sequencing and validation of novel exons

Our amplicon sequencing approach detected a total of 28 novel exons in 13 MHD risk genes. Using

RT-PCR followed by Sanger sequencing we validated 21/21 targeted novel exons (Table 1). The SZ

risk gene chloride voltage-gated channel 3 (*CLCN3*) contained four novel exons within six novel

isoforms and an example of PCR validation is shown in Supplementary Figure 12A. Validated novel

exon mean length was 99 nt, ranging from 41 nt (*CLCN3*) to 231 nt (*GRM3*). 16 (76%) of validated

novel exons were classified as 'poison exons' as they encoded a PTC (Supplementary Figure 12B),

although two of these poison exons, within *NEGR1* and *XRN2*, were <50 nt from the final exon

junction and therefore may not undergo NMD. The novel exon contained within Tx3 for *XRN2* had

the second highest isoform read count for the gene, following the canonical transcript

(ENST0000037191), with 4.7% of assigned reads. If translated, this transcript would omit an omega-

N-methylarginine modification site (ARG:946) within a disordered region at the C-terminus

(Supplementary Figure 13, Supplementary File 3AE).

Three novel exons were in untranslated regions and two were predicted to retain the ORF, including

the 42 nt exon in *NEGR1* mentioned previously and a 60 nt exon within *SORCS3*. *SORCS3* is a

member of the VPS10 transmembrane protein family and assists with neuronal protein trafficking and

sorting and a lack of *SORCS3* in the hippocampus in mice has been associated with impaired learning

and fear memory in mice [59-61]. The novel exon in Tx1, encoding 20 aa

(AMCGRAQWFTPVILALWETE), falls within the *SORCS3* lumenal region (position:

LYS:956/PRO:957) and did not appear to disrupt the transmembrane or cytoplasmic domains.

Comparison of protein prediction models of the canonical (ENST00000369701.8) and novel isoform

(Tx1) showed the addition of an unstructured loop with a partial alpha helix within the second

polycystic kidney disease (PKD2) domain (Figure 8A-D), though the prediction confidence was low,

so the structural impact on the PKD2 domain remains uncertain [52].

A

B

C

Figure 7. Brain region specific expression of novel isoforms. A. *DCC* novel transcript 9 (Tx9) uses a known (ENST00000581580) alternative 3'SS (-60 nt) in cassette exon 17 and had significantly higher read counts in CBM. **B-C.** *DOC2A* novel transcripts. Tx8 used a novel splice donor in canonical 5'UTR exon 1 (GT, +158 nt). Tx41 extended the known reference isoform ENST00000574405 to the canonical translational stop and had significantly higher reads in caudate. Brodmann's Area (BA), caudate (CAUD), cerebellum (CBM) and temporal cortex (TCX). Adjusted P value: **= $P \leq 0.01$, ***=$P \leq 0.001$, ****=$P \leq 0.0001$.

A   **B**

C   **D**

Figure 8. *SORCS3* novel exon and protein structure predictions. A. AlphaFold prediction of *SORCS3* canonical
isoform (ENST00000369701.8: Q17R88) coloured by domain: β-propeller (blue), 10CC domain domains
(green), polycystic kidney disease (PKD) domains PKD1 (orange) and PKD2 (yellow), SorCS membrane proximal
(SoMP) (red) and transmembrane domain (pink). **B.** Zoomed view of the PKD2 domain indicating LYS:956 (blue)
and PRO:957 (orange) where frame-retaining novel exon 20a (60 nt) is inserted. **C.** Protein structure prediction
of novel transcript 1 (Tx1) containing the novel exon (blue) within the PKD2 domain (yellow). **D.** AlphaFold per-
residue confidence scores (pLDDT) (0-100) for novel transcript 1: very high (>90, blue), confident (90-70, light-
blue), low (70>50, yellow) and very low (<50, orange).

Table 1. Neuropsychiatric disorder risk gene novel exon validation.

Definitions: chromosome (Chr), nucleotide (nt), open reading frame (ORF), premature termination codon (PTC), untranslated region (UTR).

Gene	Novel exon	Chr	Genomic coordinates Start	End	Size (nt)	Classification	UniProt/Pfam domain
SORCS3	20a	10	105244778	105244837	60	ORF	Lumenal
GRIA1	2a	5	153509750	153509806	57	PTC	Extracellular
XRN2	16a	20	21345834	21345887	54	PTC	None
XRN2	29a	20	21387308	21387371	64	PTC (<50nt)	Disordered
SLC30A9	6a	4	42028140	42028260	121	PTC	Helix
SLC30A9	9a	4	42059964	42060036	73	PTC	Cation efflux family
GRM3	2a	7	86776784	86777014	231	PTC	None
GRM3	3a	7	86832296	86832411	116	PTC	None
NEGR1	6a	1	71532866	71532907	42	ORF	None
NEGR1	6b	1	71587343	71587400	58	PTC (<50nt)	Transmembrane
RFTN2	1a	2	197654257	197654391	135	PTC	None
RFTN2	1b	2	197671542	197671664	123	PTC	None
RFTN2	6a	2	197616952	197617073	122	PTC	None
CNTN4	1a	3	2656485	2656587	103	PTC	None
PTK2B	3a	8	27318676	27318793	118	UTR	None
PTK2B	3a (short)	8	27318696	27318793	98	UTR	None
PTK2B	3b	8	27319918	27319985	68	UTR	None
CLCN3	1a	4	169630165	169630335	171	UTR	None
CLCN3	2a	4	169638597	169638742	146	PTC	Cytoplasmic
CLCN3	2b	4	169640168	169640208	41	PTC	Cytoplasmic
CLCN3	2c	4	169663527	169663617	91	PTC	Cytoplasmic

Discussion

In this study we used long-read sequencing to profile 31 neuropsychiatric disorder risk genes identifying 360 novel RNA isoforms. We also present a new bioinformatic tool, IsoLamp, that can accurately identify and quantify novel RNA isoforms from long-read amplicon data. The recent proliferation of GWAS studies examining increasingly large population-wide data has identified hundreds of genomic variants associated with risk of developing a mental health disorder [23, 62]. Evidence suggests that some risk variants, specifically those that are non-coding, play a role in pre-mRNA splicing and our current understanding of the transcriptomic profile for these risk genes is limited [33, 63]. A key finding of our research is both the high number of novel expressed RNA isoforms and, for some risk genes, the high expression of novel isoforms both individually and collectively. This finding reflects both the known complexity of alternative splicing in the human brain [64] and the current incompleteness of the reference transcriptome. As a result of the relatively deep sequencing afforded by this long-read approach, we have shown that there is a much higher level of RNA isoform diversity for these genes than reported in the current reference annotations. These findings provide new insight into the repertoire of RNA isoforms expressed in brain that could be important for understanding the risk and onset of neuropsychiatric disorders.

RNA isoform discovery, classification and visualisation

We generated a set of high-confidence RNA isoforms from nanopore long-read data using IsoLamp. IsoLamp optimises and streamlines transcript identification, quantification and annotation from long-read amplicon data and outperformed other methods. IsoLamp improves upon our previously published pipeline TAQLoRe [33] by expanding analysis capabilities to any gene and identifying all isoforms within a single pipeline. Our overall approach also overcomes the significant challenge of re-assembling and classifying RNA isoforms using short reads [65-67]. The primary outputs from IsoLamp, filtered transcripts (GTF) and transcript expression (TPM) is designed to be compatible with multiple downstream tools, including our visualisation tool IsoVis (https://isomix.org/isovis) (Wan et al., 2024, *under review*).

Taken together, our benchmarking results highlight that IsoLamp's optimised isoform discovery parameters, coupled with its specific filters (expression, overlapping primers, and full-length reads), yield significant improvements in both precision and recall compared to Bambu, FLAIR, FLAMES and StringTie2. The TPM filter applied to the data presented in this study is conservative and for long and complex genes may need to be tested to yield a balance of novel isoform detection and acceptable expression levels. IsoLamp also output consistent expression quantification that was robust to the quality of the annotations provided.

Novel RNA isoforms in neuropsychiatric disorders

The results presented in this study confirm our current limited understanding of RNA isoform profiles in the human brain and demonstrates how long-read sequencing technologies are a powerful tool to address this issue [32, 33, 68].

Several novel isoforms and exons were identified for ion homeostasis and channel genes *CLCN3*, *CACNA1C* and *SLC30A9* which have shared risk for SZ, BPD and ASD [21, 23, 62]. Voltage-gated ion channels are widely distributed in the brain and regulate neuronal firing. Mutations to these genes have been associated with disease and the emerging role of these channels in neuropsychiatric disorders has been previously reviewed [69]. A study of SZ, BPD and MDD patients versus controls reported gene expression changes in human striatum for potassium, calcium and chloride channel genes including *CACNA1C* and *CLCN3* [70]. *CLCN3* belongs to the CLC family of anion channels and transporters and has an established role in human neurodevelopment [71, 72]. We identified and validated four novel exons in *CLCN3*, three of which were predicted to encode a PTC which could lead to NMD. The fourth was located within the 5'UTR, an area known to impact translation

regulation in humans potentially through structural interference with the ribosome [73]. Splice
variants of *CLCNC3* have been shown to impact intracellular localisation and our results confirmed
these splice variants and further add to them, in particular a novel RNA isoform (Tx9) which is
similar to ENST0000613795, but includes the 76 bp exon 12 [71]. Twenty-two novel isoforms were
identified for calcium channel gene *CACNA1C* and supporting previous findings [33] the top ten
novel isoforms, by assigned read count, were classified as frame retaining, supporting their potential
to generate functional proteins. *SLC30A9* (first known as *HUEL*) encodes the zinc transporter protein
9 (ZnT9) which is involved in zinc transport and homeostasis in the endoplasmic reticulum and also
localises to the cytoplasm and nucleus [74]. Whilst the function of the protein is not fully understood,
a 3 nt familial deletion (c.1047_1049delGCA) in the highly conserved cation efflux domain (CED)
has been recorded to result in changes to protein structure, intracellular zinc levels and intellectual
disability [75, 76]. Critically, we identified and validated a novel exon (Tx3-9a:73 nt) within this CED
providing evidence that this region may be alternatively spliced more commonly than previously
understood, potentially impacting protein function [74].

Several novel exons were detected in the long reads for post-mortem brains used in this study.
Previous studies have identified approximately 250 conserved neuronal micro-exons (3-27 nt) that
typically preserve the ORF and are involved in neuronal differentiation [77, 78]. Although not
classified as micro-exons, a third (N=7) of the validated novel exons found in post-mortem brain in
our study were <65 nt, similar to previously reported exon lengths that are difficult for the splicing
machinery to process, indicating that these exons may also be inefficiently spliced [79]. Micro-exons
are known to be disrupted, usually through increased skipping events, in the brains of individuals with
ASD [78, 80]. Importantly, we identified novel exons in two ASD risk genes, *SORCS3* and *XRN2*.
SORCS3, which has remarkable shared neuropsychiatric disorder risk, contained a novel exon (22 aa)
predicted to preserve the reading frame [59, 81]. How these novel exons impact expression or
function of a mature protein remains unknown. Further studies with a focus on the transcriptional
landscape in the developing brain will be crucial in furthering our understanding of these splicing
events [80].

Limitations and future directions

712
The results of our study are limited by the sample size of available control post-mortem brain tissue.
The nanopore long-read data for each risk gene was generated from five elderly, male control
individuals, with a single female sample removed from further analyses due to quality constraints.
These results may not be representative of all populations, particularly when it comes to novel exons
and lowly expressed novel RNA isoforms. Individual transcriptome-wide variation has been observed
between age, sex and pathology [82, 83], despite this we did not detect high levels of individual
isoform expression variation and novel isoforms were almost always present in all individuals. The
small number of available individuals means this dataset was not powered to investigate genotype
impacts on isoform expression, though this will be an important area of investigation to determine
which risk genotypes act through changes in isoform structure and/or expression.

Sample and RNA quality, as measured by RINe, is critical to high-quality sequencing and this is
especially true for long reads [33, 84]. Supporting previous findings in mRNA, our data suggest that
pH values <6.3 impacted the quality of post-mortem human brain RNA, which is especially critical
for robust amplification of longer (>5 Kb) CDS [85]. In general, PCR cycling was kept as low as
possible to avoid PCR bias towards shorter isoforms and other artifacts. However, we noted that lower
RINs, as recorded for Ind04, appeared to impact amplicons of longer CDS. To help overcome such
issues, future long-read amplicon sequencing could incorporate unique molecular identifiers to tag
molecules prior to PCR to ensure an accurate representation of the original RNA isoforms [86].

The risk genes profiled in this study were selected based on multiple levels of evidence for their
involvement in risk, not only from GWAS but from meta-analyses and further independent studies

[22, 25]. Whilst this approach was expected to produce a set of genes with high-confidence of their involvement in disorder risk, it is not exhaustive and it will be important to ensure risk gene lists are updated as more evidence from GWAS and other studies becomes available [25, 63]. Genes that are thought to confer resistance to the development of neuropsychiatric disease are also beginning to emerge and the addition investigation of their expression and isoform profiles may also provide valuable insight into disease risk and progression [87]. Additionally, combining whole or amplicon transcriptomic data, large-scale proteomic data and machine-learning predictive models like TRIFID can help to identify and prioritise functional proteomic isoforms [88].

Conclusion

In conclusion, we identified several hundred unreported RNA isoforms and novel exons, many of which could impact the function of known neuropsychiatric risk genes that also play crucial roles in normal neuronal development and activity. An understanding of the regulatory and functional impacts of these novel isoforms and incorporating long-read Nanopore data into existing repositories will help form an important knowledge base of alternative splicing in the human brain [89, 90]. Some novel isoforms or exons may also be future therapeutic targets through the modulation of splice isoforms using antisense oligonucleotides or CRISPR technology.

Conflict of interest

RDP, YP, YY, JG and MBC have received financial support from Oxford Nanopore Technologies (ONT) to present their findings at scientific conferences. ONT played no role in study design, execution, analysis or publication.

Data availability

All raw nanopore long-read data (fastq) generated for each of the genes reported in this manuscript will be uploaded to The European Genome-Phenome Archive (EGA) upon publication. Isoform GTFs and counts tables from IsoLamp analysis are available upon request. Scripts used for long-read data preparation and downstream data analysis are also available in supplementary material or upon request. IsoLamp is open source and freely available (https://github.com/ClarkLaboratory/IsoLamp). IsoVis is freely available (https://isomix.org/isovis/).

Acknowledgements

The authors would like to acknowledge that brain tissues were received from the Victorian Brain Bank (VBB), supported by The Florey, The Alfred and the Victorian Institute of Forensic Medicine and funded in part by Parkinson's Victoria, MND Victoria and FightMND. The authors would also like to thank Geoff Pavey at the VBB for his assistance with frozen tissue preparation. This research was supported by The University of Melbourne's Research Computing Services and the Petascale Campus Initiative.

References

1. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ: **Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing.** *Nature genetics* 2008, **40:**1413-1415.
2. Kelemen O, Convertini P, Zhang Z, Wen Y, Shen M, Falaleeva M, Stamm S: **Function of alternative splicing.** *Gene* 2013, **514:**1-30.
3. Nilsen TW, Graveley BR: **Expansion of the eukaryotic proteome by alternative splicing.** *Nature* 2010, **463:**457-463.
4. Leung SK, Jeffries AR, Castanho I, Jordan BT, Moore K, Davies JP, Dempster EL, Bray NJ, O'Neill P, Tseng E: **Full-length transcript sequencing of human and mouse cerebral cortex identifies widespread isoform diversity and alternative splicing.** *Cell reports* 2021, **37**.
5. Mazin P, Xiong J, Liu X, Yan Z, Zhang X, Li M, He L, Somel M, Yuan Y, Phoebe Chen YP: **Widespread splicing changes in human brain development and aging.** *Molecular systems biology* 2013, **9:**633.
6. Baralle FE, Giudice J: **Alternative splicing as a regulator of development and tissue identity.** *Nature reviews Molecular cell biology* 2017, **18:**437-451.
7. De Paoli-Iseppi R, Gleeson J, Clark MB: **Isoform Age-Splice Isoform Profiling Using Long-Read Technologies.** *Frontiers in Molecular Biosciences* 2021, **8**.
8. Castaldi PJ, Abood A, Farber CR, Sheynkman GM: **Bridging the splicing gap in human genetics with long-read RNA sequencing: finding the protein isoform drivers of disease.** *Human Molecular Genetics* 2022, **31:**R123-R136.
9. Stanley RF, Abdel-Wahab O: **Dysregulation and therapeutic targeting of RNA splicing in cancer.** *Nature cancer* 2022, **3:**536-546.
10. Vitting-Seerup K, Sandelin A: **IsoformSwitchAnalyzeR: analysis of changes in genome-wide patterns of alternative splicing and its functional consequences.** *Bioinformatics* 2019, **35:**4469-4471.
11. Manuel JM, Guilloy N, Khatir I, Roucou X, Laurent B: **Re-evaluating the impact of alternative RNA splicing on proteomic diversity.** *Frontiers in Genetics* 2023, **14:**1089053.
12. Melé M, Ferreira PG, Reverter F, DeLuca DS, Monlong J, Sammeth M, Young TR, Goldmann JM, Pervouchine DD, Sullivan TJ: **The human transcriptome across tissues and individuals.** *Science* 2015, **348:**660-665.
13. Carvill GL, Engel KL, Ramamurthy A, Cochran JN, Roovers J, Stamberger H, Lim N, Schneider AL, Hollingsworth G, Holder DH: **Aberrant inclusion of a poison exon causes dravet syndrome and related SCN1A-associated genetic epilepsies.** *The American Journal of Human Genetics* 2018, **103:**1022-1029.
14. Lara-Pezzi E, Desco M, Gatto A, Gómez-Gaviro MV: **Neurogenesis: regulation by alternative splicing and related posttranscriptional processes.** *The Neuroscientist* 2017, **23:**466-477.
15. Rehm J, Shield KD: **Global Burden of Disease and the Impact of Mental and Addictive Disorders.** *Current Psychiatry Reports* 2019, **21:**10.
16. Sandell C, Kjellberg A, Taylor RR: **Participating in diagnostic experience: adults with neuropsychiatric disorders.** *Scandinavian Journal of Occupational Therapy* 2013, **20:**136-142.
17. Bray NJ, O'Donovan MC: **The genetics of neuropsychiatric disorders.** *Brain and neuroscience advances* 2018, **2:**2398212818799271.
18. Medalia A, Saperstein AM, Hansen MC, Lee S: **Personalised treatment for cognitive dysfunction in individuals with schizophrenia spectrum disorders.** *Neuropsychological rehabilitation* 2018, **28:**602-613.
19. Mora C, Zonca V, Riva MA, Cattaneo A: **Blood biomarkers and treatment response in major depression.** *Expert review of molecular diagnostics* 2018, **18:**513-529.
20. Anney RJL, Ripke S, Anttila V, Grove J, Holmans P, Huang H, Klei L, Lee PH, Medland SE, Neale B, et al: **Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder**

818		**highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia.**
819		*Molecular Autism* 2017, **8:**21.
820	21.	Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, Pallesen J, Agerbo E, Andreassen
821		OA, Anney R: **Identification of common genetic risk variants for autism spectrum disorder.**
822		*Nature genetics* 2019, **51:**431-444.
823	22.	Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, Legge SE, Bishop
824		S, Cameron D, Hamshere ML: **Common schizophrenia alleles are enriched in mutation-**
825		**intolerant genes and in regions under strong background selection.** *Nature genetics* 2018,
826		**50:**381.
827	23.	Ripke S, Neale BM, Corvin A, Walters JT, Farh K-H, Holmans PA, Lee P, Bulik-Sullivan B, Collier
828		DA, Huang H: **Biological insights from 108 schizophrenia-associated genetic loci.** *Nature*
829		2014, **511:**421.
830	24.	Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, Mattheisen M, Wang Y,
831		Coleman JR, Gaspar HA: **Genome-wide association study identifies 30 loci associated with**
832		**bipolar disorder.** *Nature genetics* 2019, **51:**793-803.
833	25.	Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, Bryois J, Chen
834		C-Y, Dennison CA, Hall LS: **Mapping genomic loci implicates genes and synaptic biology in**
835		**schizophrenia.** *Nature* 2022, **604:**502-508.
836	26.	Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, Montgomery GW, Goddard ME,
837		Wray NR, Visscher PM: **Integration of summary data from GWAS and eQTL studies predicts**
838		**complex trait gene targets.** *Nature genetics* 2016, **48:**481-487.
839	27.	Sey NY, Hu B, Mah W, Fauni H, McAfee JC, Rajarajan P, Brennand KJ, Akbarian S, Won H: **A**
840		**computational tool (H-MAGMA) for improved prediction of brain-disorder risk genes by**
841		**incorporating brain chromatin interaction profiles.** *Nature Neuroscience* 2020, **23:**583-593.
842	28.	Yang A, Chen J, Zhao X-M: **nMAGMA: a network-enhanced method for inferring risk genes**
843		**from GWAS summary statistics and its application to schizophrenia.** *Briefings in*
844		*bioinformatics* 2021, **22:**bbaa298.
845	29.	Devlin B, Kelsoe JR, Sklar P, Daly MJ, O'Donovan MC, Craddock N, Sullivan PF, Smoller JW,
846		Kendler KS: **Genetic relationship between five psychiatric disorders estimated from**
847		**genome-wide SNPs.** *Nature genetics* 2013, **45:**984-994.
848	30.	Steijger T, Abril JF, Engström PG, Kokocinski F, Hubbard TJ, Guigó R, Harrow J, Bertone P:
849		**Assessment of transcript reconstruction methods for RNA-seq.** *Nature methods* 2013,
850		**10:**1177-1184.
851	31.	Amarasinghe SL, Su S, Dong X, Zappia L, Ritchie ME, Gouil Q: **Opportunities and challenges**
852		**in long-read sequencing data analysis.** *Genome biology* 2020, **21:**1-16.
853	32.	Glinos DA, Garborcauskas G, Hoffman P, Ehsan N, Jiang L, Gokden A, Dai X, Aguet F, Brown
854		KL, Garimella K: **Transcriptome variation in human tissues revealed by long-read**
855		**sequencing.** *Nature* 2022, **608:**353-359.
856	33.	Clark MB, Wrzesinski T, Garcia AB, Hall NAL, Kleinman JE, Hyde T, Weinberger DR, Harrison
857		PJ, Haerty W, Tunbridge EM: **Long-read sequencing reveals the complex splicing profile of**
858		**the psychiatric risk gene CACNA1C in human brain.** *Molecular Psychiatry* 2020, **25:**37-47.
859	34.	Ma L, Semick SA, Chen Q, Li C, Tao R, Price AJ, Shin JH, Jia Y, Consortium B, Brandon NJ:
860		**Schizophrenia risk variants influence multiple classes of transcripts of sorting nexin 19**
861		**(SNX19).** *Molecular psychiatry* 2020, **25:**831-843.
862	35.	Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, McMahon A,
863		Morales J, Mountjoy E, Sollis E: **The NHGRI-EBI GWAS Catalog of published genome-wide**
864		**association studies, targeted arrays and summary statistics 2019.** *Nucleic acids research*
865		2019, **47:**D1005-D1012.
866	36.	Nassar LR, Barber GP, Benet-Pagès A, Casper J, Clawson H, Diekhans M, Fischer C, Gonzalez
867		JN, Hinrichs AS, Lee BT: **The UCSC genome browser database: 2023 update.** *Nucleic acids*
868		*research* 2023, **51:**D1188-D1195.

37.   Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JA: **Primer3Plus, an**
enhanced web interface to Primer3. *Nucleic acids research* 2007, **35:**W71-W74.
38.   Raney BJ, Dreszer TR, Barber GP, Clawson H, Fujita PA, Wang T, Nguyen N, Paten B, Zweig
AS, Karolchik D: **Track data hubs enable visualization of user-defined genome-wide**
annotations on the UCSC Genome Browser. *Bioinformatics* 2014, **30:**1003-1005.
39.   Kuhn RM, Haussler D, Kent WJ: **The UCSC genome browser and associated tools.** *Briefings in*
bioinformatics 2013, **14:**144-161.
40.   Bushnell B: **BBMap: a fast, accurate, splice-aware aligner.** Lawrence Berkeley National
Lab.(LBNL), Berkeley, CA (United States); 2014.
41.   Li H: **Minimap2: pairwise alignment for nucleotide sequences.** *Bioinformatics* 2018,
34:3094-3100.
42.   Chen Y, Sim A, Wan YK, Yeo K, Lee JJX, Ling MH, Love MI, Göke J: **Context-aware transcript**
quantification from long-read RNA-seq data with Bambu. *Nature Methods* 2023:1-9.
43.   Quinlan AR: **BEDTools: the Swiss-army tool for genome feature analysis.** *Current protocols*
in bioinformatics 2014, **47:**11.12. 11-11.12. 34.
44.   Pertea G, Pertea M: **GFF utilities: GffRead and GffCompare.** *F1000Research* 2020, **9**.
45.   Patro R, Duggal G, Kingsford C: **Salmon: accurate, versatile and ultrafast quantification from**
RNA-seq data using lightweight-alignment. 2015.
46.   Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C: **Salmon provides fast and bias-aware**
quantification of transcript expression. *Nature methods* 2017, **14:**417-419.
47.   Kovaka S, Zimin AV, Pertea GM, Razaghi R, Salzberg SL, Pertea M: **Transcriptome assembly**
from long-read RNA-seq alignments with StringTie2. *Genome biology* 2019, **20:**1-13.
48.   Tang AD, Soulette CM, van Baren MJ, Hart K, Hrabeta-Robinson E, Wu CJ, Brooks AN: **Full-**
length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia
reveals downregulation of retained introns. *Nature communications* 2020, **11:**1438.
49.   Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL: **Primer-BLAST: a tool to**
design target-specific primers for polymerase chain reaction. *BMC bioinformatics* 2012,
13:1-11.
50.   Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates
R, Žídek A, Potapenko A: **Highly accurate protein structure prediction with AlphaFold.**
Nature 2021, **596:**583-589.
51.   Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, Ferrin TE: **UCSF**
ChimeraX: Structure visualization for researchers, educators, and developers. *Protein*
Science 2021, **30:**70-82.
52.   Mirdita M, Schütze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M: **ColabFold: making**
protein folding accessible to all. *Nature methods* 2022, **19:**679-682.
53.   Tian L, Jabbari JS, Thijssen R, Gouil Q, Amarasinghe SL, Voogd O, Kariyawasam H, Du MR,
Schuster J, Wang C: **Comprehensive characterization of single-cell full-length isoforms in**
human and mouse with long-read sequencing. *Genome biology* 2021, **22:**1-24.
54.   Tardaguila M, De La Fuente L, Marti C, Pereira C, Pardo-Palacios FJ, Del Risco H, Ferrell M,
Mellado M, Macchietto M, Verheggen K: **SQANTI: extensive characterization of long-read**
transcript sequences for quality control in full-length transcriptome identification and
quantification. *Genome research* 2018, **28:**396-411.
55.   Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A: **ExPASy: the proteomics**
server for in-depth protein knowledge and analysis. *Nucleic acids research* 2003, **31:**3784-
3788.
56.   Pihl R, Jensen RK, Poulsen EC, Jensen L, Hansen AG, Thøgersen IB, Dobó J, Gál P, Andersen
GR, Enghild JJ: **ITIH4 acts as a protease inhibitor by a novel inhibitory mechanism.** *Science*
advances 2021, **7:**eaba7381.

57. Schreiner D, Nguyen T-M, Russo G, Heber S, Patrignani A, Ahrné E, Scheiffele P: **Targeted**
combinatorial alternative splicing generates brain region-specific repertoires of neurexins.
Neuron 2014, **84:**386-398.
58. Joglekar A, Prjibelski A, Mahfouz A, Collier P, Lin S, Schlusche AK, Marrocco J, Williams SR,
Haase B, Hayes A, et al: **A spatially resolved brain region- and cell type-specific isoform**
atlas of the postnatal mouse brain. *Nature Communications* 2021, **12:**463.
59. Kamran M, Laighneach A, Bibi F, Donohoe G, Ahmed N, Rehman AU, Morris DW:
Independent Associated SNPs at SORCS3 and Its Protein Interactors for Multiple Brain-
Related Disorders and Traits. *Genes* 2023, **14:**482.
60. Dong F, Wu C, Jiang W, Zhai M, Li H, Zhai L, Zhang X: **Cryo-EM structure studies of the**
human VPS10 domain-containing receptor SorCS3. *Biochemical and Biophysical Research*
Communications 2022, **624:**89-94.
61. Breiderhoff T, Christiansen GB, Pallesen LT, Vaegter C, Nykjaer A, Holm MM, Glerup S,
Willnow TE: **Sortilin-related receptor SORCS3 is a postsynaptic modulator of synaptic**
depression and fear extinction. *PloS one* 2013, **8:**e75006.
62. Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JR, Qiao Z, Als TD, Bigdeli TB,
Børte S, Bryois J: **Genome-wide association study of more than 40,000 bipolar disorder**
cases provides new insights into the underlying biology. *Nature genetics* 2021, **53:**817-829.
63. Kim M, Vo DD, Jops CT, Wen C, Patoway A, Bhattacharya A, Yap CX, Zhou H, Gandal MJ:
Multivariate variance components analysis uncovers genetic architecture of brain isoform
expression and novel psychiatric disease mechanisms. *medRxiv* 2022:2022.2010.
2018.22281204.
64. Yeo G, Holste D, Kreiman G, Burge CB: **Variation in alternative splicing across human**
tissues. *Genome biology* 2004, **5:**1-15.
65. Sarantopoulou D, Brooks TG, Nayak S, Mrčela A, Lahens NF, Grant GR: **Comparative**
evaluation of full-length isoform quantification from RNA-Seq. *BMC bioinformatics* 2021,
22:1-24.
66. Hu Y, Fang L, Chen X, Zhong JF, Li M, Wang K: **LIQA: long-read isoform quantification and**
analysis. *Genome biology* 2021, **22:**182.
67. Zhang C, Zhang B, Lin L-L, Zhao S: **Evaluation and comparison of computational tools for**
RNA-seq isoform quantification. *BMC genomics* 2017, **18:**1-11.
68. Arendt-Tranholm A, Mwirigi JM, Price TJ: **RNA isoform expression landscape of the human**
dorsal root ganglion (DRG) generated from long read sequencing. *bioRxiv* 2023:2023.2010.
2028.564535.
69. Imbrici P, Conte Camerino D, Tricarico D: **Major channels involved in neuropsychiatric**
disorders and therapeutic perspectives. *Frontiers in Genetics* 2013, **4**.
70. Smolin B, Karry R, Gal-Ben-Ari S, Ben-Shachar D: **Differential expression of genes encoding**
neuronal ion-channel subunits in major depression, bipolar disorder and schizophrenia:
implications for pathophysiology. *International Journal of Neuropsychopharmacology* 2012,
15:869-882.
71. Guzman RE, Miranda-Laferte E, Franzen A, Fahlke C: **Neuronal ClC-3 splice variants differ in**
subcellular localizations, but mediate identical transport functions. *Journal of Biological*
Chemistry 2015, **290:**25851-25862.
72. Duncan AR, Polovitskaya MM, Gaitán-Peñas H, Bertelli S, VanNoy GE, Grant PE, O'Donnell-
Luria A, Valivullah Z, Lovgren AK, England EM: **Unique variants in CLCN3, encoding an**
endosomal anion/proton exchanger, underlie a spectrum of neurodevelopmental
disorders. *The American Journal of Human Genetics* 2021, **108:**1450-1465.
73. Leppek K, Das R, Barna M: **Functional 5' UTR mRNA structures in eukaryotic translation**
regulation and how to find them. *Nature reviews Molecular cell biology* 2018, **19:**158-174.

74.   Roca-Umbert A, Garcia-Calleja J, Vogel-González M, Fierro-Villegas A, Ill-Raga G, Herrera-
Fernández V, Bosnjak A, Muntané G, Gutiérrez E, Campelo F: **Human genetic adaptation**
related to cellular zinc homeostasis. *Plos Genetics* 2023, **19:**e1010950.

75.   Perez Y, Shorer Z, Liani-Leibson K, Chabosseau P, Kadir R, Volodarsky M, Halperin D, Barber-
Zucker S, Shalev H, Schreiber R: **SLC30A9 mutation affecting intracellular zinc homeostasis**
causes a novel cerebro-renal syndrome. *Brain* 2017, **140:**928-939.

76.   Willekens J, Runnels LW: **Impact of Zinc Transport Mechanisms on Embryonic and Brain**
Development. *Nutrients* 2022, **14:**2526.

77.   Gonatopoulos-Pournatzis T, Blencowe BJ: **Microexons: at the nexus of nervous system**
development, behaviour and autism spectrum disorder. *Current Opinion in Genetics &*
Development 2020, **65:**22-33.

78.   Irimia M, Weatheritt RJ, Ellis JD, Parikshak NN, Gonatopoulos-Pournatzis T, Babor M,
Quesnel-Vallières M, Tapial J, Raj B, O'Hanlon D: **A highly conserved program of neuronal**
microexons is misregulated in autistic brains. *Cell* 2014, **159:**1511-1523.

79.   Li YI, Sanchez-Pulido L, Haerty W, Ponting CP: **RBFOX and PTBP1 proteins regulate the**
alternative splicing of micro-exons in human brain transcripts. *Genome research* 2015,
25:1-13.

80.   Chau KK, Zhang P, Urresti J, Amar M, Pramod AB, Chen J, Thomas A, Corominas R, Lin GN,
Iakoucheva LM: **Full-length isoform transcriptome of the developing human brain provides**
further insights into autism. *Cell reports* 2021, **36**.

81.   Wu Y, Cao H, Baranova A, Huang H, Li S, Cai L, Rao S, Dai M, Xie M, Dou Y: **Multi-trait**
analysis for genome-wide association study of five psychiatric disorders. *Translational*
psychiatry 2020, **10:**209.

82.   Peters MJ, Joehanes R, Pilling LC, Schurmann C, Conneely KN, Powell J, Reinmaa E, Sutphin
GL, Zhernakova A, Schramm K: **The transcriptional landscape of age in human peripheral**
blood. *Nature communications* 2015, **6:**1-14.

83.   Işıldak U, Somel M, Thornton JM, Dönertaş HM: **Temporal changes in the gene expression**
heterogeneity during brain development and aging. *Scientific reports* 2020, **10:**4080.

84.   Prawer YD, Gleeson J, De Paoli-Iseppi R, Clark MB: **Pervasive effects of RNA degradation on**
Nanopore direct RNA sequencing. *NAR Genomics and Bioinformatics* 2023, **5:**lqad060.

85.   Harrison PJ, Heath PR, Eastwood SL, Burnet PWJ, McDonald B, Pearson RCA: **The relative**
importance of premortem acidosis and postmortem interval for human brain gene
expression studies: selective mRNA vulnerability and comparison with their encoded
proteins. *Neuroscience Letters* 1995, **200:**151-154.

86.   Karst SM, Ziels RM, Kirkegaard RH, Sørensen EA, McDonald D, Zhu Q, Knight R, Albertsen M:
High-accuracy long-read amplicon sequences using unique molecular identifiers with
Nanopore or PacBio sequencing. *Nature methods* 2021, **18:**165-169.

87.   Hess JL, Tylee DS, Mattheisen M, Børglum AD, Als TD, Grove J, Werge T, Mortensen PB: **A**
polygenic resilience score moderates the genetic risk for schizophrenia. *Molecular*
psychiatry 2021, **26:**800-815.

88.   Pozo F, Martinez-Gomez L, Walsh TA, Rodriguez JM, Di Domenico T, Abascal F, Vazquez J,
Tress ML: **Assessing the functional relevance of splice isoforms.** *NAR Genomics and*
Bioinformatics 2021, **3:**lqab044.

89.   Dawes R, Bournazos AM, Bryen SJ, Bommireddipalli S, Marchant RG, Joshi H, Cooper ST:
SpliceVault predicts the precise nature of variant-associated mis-splicing. *Nature Genetics*
2023, **55:**324-332.

90.   Frankish A, Carbonell-Sala S, Diekhans M, Jungreis I, Loveland JE, Mudge JM, Sisu C, Wright
JC, Arnan C, Barnes I: **GENCODE: reference annotation for the human and mouse genomes**
in 2023. *Nucleic acids research* 2023, **51:**D942-D949.

91.   Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, Hasz R, Walters G, Garcia F, Young
N: **The genotype-tissue expression (GTEx) project.** *Nature genetics* 2013, **45:**580-585.

1018

1019

Supplementary Figures

Supplementary Figure 1. Mental health disorder (MHD) risk gene list curation pipeline. A.
Single nucleotide polymorphism (SNP) catalogues form the foundation of the final risk gene evidence
lists used to select genes for amplicon sequencing. These catalogues are collated from up-to-date,
large-scale genome wide association studies (GWAS) of MHDs. A single GWAS catalogue was
downloaded for schizophrenia (SZ), major depressive disorder (MDD), bipolar disorder (BD) and
autism spectrum disorder (ASD), and associations were filtered according to criteria in Supplementary
Table 2. GWAS data generally had either a mapped or reported gene associated with each SNP.
Further evidence (i.e. reported genes) from categorised literature sources (shown in green) was then
added to the list. This list was then sorted (high to low) by the number of occurrences of a risk gene in
unique studies across all evidence/validation categories. No weighting was applied to any category. A
multi-trait list was also made containing evidence for risk genes across all four MHDs so shared risk
genes could be identified. **B.** An example of additional risk gene information included in the list e.g.
for *GNL3*, count of known transcripts, count of coding exons for the canonical isoform, length in
nucleotides (nt), length of protein in amino acids (aa) and the categorised Genotype-Tissue
Expression (GTEx) in transcript per million (TPM) for each brain tissue [91]. *Definitions*: multi-
marker analysis of Genomic annotation (MAGMA), summary-based Mendelian randomisation
(SMR), transcriptome wide association study (TWAS).

1039 **Supplementary Figure 2.** Experimental design of SIRV amplicon controls. E0, E1 and E2 represent
1040 each SIRV mix of known isoform concentrations. Each mix was converted into cDNA in triplicate
1041 and finally, the full length of synthetic genes SIRV5 and 6 were amplified using PCR in triplicate for
1042 each cDNA replicate.

1043

Supplementary Figure 3. Benchmarking IsoLamp using spike-in SIRVs and the optimised
IsoLamp expression-based filter. A. Precision recall of each tested pipeline with the complete,
insufficient or over annotated SIRV reference, filtering all results using the IsoLamp expression-based
filter. IsoLamp (black) returned high quality isoforms from amplicon data of both SIRV5 and 6.
Pearson **(B)** and Spearman **(C)** correlations for each pipeline between known and observed expression
values for SIRV 5 and 6 mixes.

1050

1051

Supplementary Figure 4. Post-mortem human brain RNA QC. A. Yield of isolated total
RNA generally increases with increased tissue weight (mg) input to homogenisation using the
RNeasy Lipid Tissue Mini Kit (QIAGEN:74804). **B.** The RNA integrity number equivalent
(RINe) for brain tissue was generally between 7 – 8. RINe from individual (Ind) 04 was
significantly lower when compared to Individuals 01 and 05. **C.** No correlation was detected
between RNA quality (RINe) and individual post-mortem interval (PMI). **D.** Decreasing
individual brain pH appears to impact RINe. Half-circles indicate samples from individual 04
(pH = 6.3). Full circles indicate degraded RNA isolated from individual 06 which were not
included for further analysis. Data in B, C and D are staggered for clarity.

A   **B**

C   **D**

1063

Supplementary Figure 5. Principal component analyses (PCA) of brain samples. PC1 and PC2 coloured by RNA integrity (RIN) **(A)** and brain region **(B)**. **C.** PC4 and PC5 coloured by donor age (years). Key: individual (ind), Brodmann's area (BA), caudate (caud), cerebellum (cbm) and temporal cortex (TCX).

A

B

C

1072 **Supplementary Figure 6. Long-read amplicon mapping accuracy. A.** All sequenced risk genes.
1073 Plotted range 0.85 – 1.00. **B.** A box and whiskers plot of the median accuracy for each risk gene.
1074 Open circles indicate the library was prepared with ligation sequencing kit 110 (ONT). Colours
1075 indicate flow cells that were used multiple times (N=3-5).

1076 **A**

1077

1078 **B**

1079

Supplementary Figure 7. Risk gene isoform counts. The number of detected isoforms (known and novel) is shown for each risk gene sorted from lowest (*GRIN2A*) to highest (*ITIH4*). Each isoform was classified into a SQANTI subcategory: reference match (RM), containing at least one novel splice site (ALO), retained intron (RI), combination of known junctions (COJ) or splice sites (COS). Known (RM) isoform counts are plotted on the right Y-axis and novel isoform counts are plotted on the left Y-axis.

Supplementary Figure 8. Linear regression of amplicon length or canonical exon count against
isoform count and novel isoform TPM proportion does not deviate significantly from zero.
Linear regression of known and novel isoform counts with expected canonical amplicon length (**A**)
and number of canonical exons (**B**). Linear regression of novel isoform read proportion with expected
canonical amplicon length (**C**) and number of canonical exons (**D**).

A

1094

1095 **C**

1096

1097

1098 **Supplementary Figure 9. A.** Count of novel isoform splice pairing. Isoforms classified as containing
1099 at least one novel splice site (ALO) were examined and the novel pair or donor/acceptor was counted.

1100 **A**

1101

1102

 Supplementary Figure 10. UCSC screenshot of *CACNA1C* splicing hotspot. Long-read
1104 sequencing identified 10 novel isoforms (black tracks) that support one of two annotated alternative
1105 splicing events (yellow boxes) within a 12 nt region (chr12:2,493,190-2,493,201) of exon 7 in
1106 *CACNA1C*. 11 novel isoforms also supported the use of the canonical (ENST00000399655.6)
1107 acceptor site (green box).

1108

1109

1110

Supplementary Figure 11. *NEGR1* **splice isoforms and protein prediction. A.** The IsoVis
schematic of *NEGR1* known and novel isoforms. Protein track indicates 5' signal peptide (brown) and
three immunoglobulin (Ig)-like domains (red). **B.** NEGR1 pre-mRNA splice graph and predicted
mRNA outcome. **C.** *NEGR1* novel exons were validated using Sanger sequencing of PCR amplicons
and sequence reads were aligned and viewed using UCSC Genome Browser. Orange boxes indicate
the novel exons and highlight high vertebrate conservation for exon 6b and predicted (NCBI RefSeq)
termination site for exon 6a. **D.** AlphaFold protein prediction of the canonical *NEGR1* isoform
(ENST00000357731). Three Ig-like domains are coloured according to the reported amino-acid
positions (UniProt: Q7Z3B1); 1 (orange), 2 (blue) and 3 (pink). A GPI anchor residue (red) is shown
at position 324 aa (C-terminal, red arrow). **E.** Overlaid AlphaFold protein predictions of novel Tx1
(purple) and Tx2 (orange). Ig-like domains are numbered 1-3, the GPI anchor (red) is present in Tx1
and the termination of Tx is indicated by a red arrow. Novel residues (pink) are indicated at the C-
terminal end for both transcripts, Tx1: 14 aa and Tx2: 7 aa.

A

1125

1126 **B**

1127

1128 **C**

1129

1130

1131

1132

1133   **D**

1134

1135   **E**

1136

1137

Supplementary Figure 12A. Novel exon validation in *CLCN3*. Novel exon 2a in the schizophrenia
risk gene *CLCN3*, identified in long-read sequencing data, was validated by PCR using primers
designed in the flanking cassette exons 1 and 3 (ENST00000513761). The novel exon sequence
shown in novel transcript (Tx) 2 was validated with Sanger sequencing from the 5' canonical exon 2
(C2F1) to the reverse primer within the novel sequence (N2aR1) and from the novel sequence
(N2aF1) to the 3' canonical exon 3 (C3R1). Direction of reads are indicated with arrows. Black and
orange boxes indicate forward and reverse Sanger sequence respectively. Blue boxes indicate forward
and reverse primers within the novel exon. A known cytoplasmic domain is shown by an orange
track. Key: expressed sequence tag (EST). **B. Novel exon categories.** The impact of novel exon
inclusion on the open reading frame of novel isoforms was predicted using Expasy [55] and then
classed into groups, predicted to retain the open reading frame (ORF), inclusion of premature
termination codon or 'poison exon' that was predicted to lead to nonsense-mediated decay (PE:NMD)
or was <50 nt from the final exon junction (PE: <50 nt) or was with the 5' or 3' untranslated regions
(UTR).

A

1153

1154 **B**

1155

Supplementary Figure 13. Splice graph of *XRN2* novel isoforms containing novel exons. Dark
and light grey boxes indicate 5' and 3' UTR and coding exons respectively. Orange lines and boxes
indicate novel splicing events and exons. Novel transcript 1 (Tx1) contains a novel splice acceptor
(AG) within exon 14 (+24 nt) leading to a premature termination codon (PTC) and predicted nonsense
mediated decay. Novel transcript 2 (Tx2) includes the validated novel exon 16a (54 nt) which was
also predicted to encode a PTC. Novel isoform 3 (Tx3) contains a validated novel exon (29a) which
encodes a PTC <50 nt from the final exon junction. Tx3 was predicted to lead to a truncated protein
(934 aa). ".." indicates 0's removed for brevity.

44